NK
Neil Kumar (Chief Executive Officer) filed 14 Form 4 reports in the trailing twelve months (0 purchases, 14 sales), most often in BridgeBio Pharma, Inc. (BBIO). The largest single filing was $6.0M of BBIO (80,000 sh across 8 lots, as filed), executed Apr 9. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
14
0 buys · 14 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$49.7M
shares × price, as filed
Last traded
Sep 17
Filed Sep 21
Median ADV $293.8M across their filed names
Open performance→Volume by month
Buys $0
Sells $107.1M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
13 filings
Sector per market data · by filing · past 12 months
Most traded names
BBIORecent filings
BBIOSALE
BridgeBio Pharma, Inc.
View filing →
$21.8M600,000 sh across 3 lots
Exec Jan 28 2025
Filed Jan 30 2025 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. View filing → $571K
25,514 sh × $22.39
Exec Nov 19 2024
Filed Nov 20 2024 · 5:30 PM ET